1 Prevalence of Coronary Atherosclerosis in Master Female Endurance Athletes

2	Efstathios Papatheodorou ¹ , Vincent L. Aengevaeren ² , Thijs M.H. Eijsvogels ² , Khaled Al
3	Fakih ³ , Rebecca Kathryn Hughes ⁴ , Ahmed Merghani ¹ , Christine K. Kissel ¹ , Saad Fyyaz ¹ ,
4	Athanasios Bakalakos ¹ , Mathew G. Wilson ^{5,6} , Damini Dey ⁷ , Gherardo Finocchiaro ¹ ,
5	Gemma Parry-Williams ¹ , Camilla Torlasco ⁴ , Michael Papadakis ¹ , James C. Moon ⁴ ,
6	Sanjay Sharma ¹ .

8	1.	Cardiology Clinical and Academic Group. St Georges, University of London,
9		and St George's University Hospital NHS Foundation Trust (UK)
10	2.	Department of Medical Biosciences, Exercise Physiology Research Group.
11		Radboud University Medical Centre. Nijmegen, the Netherlands
12	3.	University Hospital Lewisham, London (UK)
13	4.	The Barts Heart Centre, University College London (UK)
14	5.	Institute of Sport and Exercise Health (ISEH), University College London,
15		London, UK
16	6.	HCA Healthcare Research Institute, London, UK
17	7.	Cedars-Sinai Medical Centre, Biomedical Imaging Research Institute, Los
18		Angeles, CA (USA)
19		
20		
21	Addre	ss for correspondence:
22	Sanjay	Sharma
23	Profes	sor of Cardiology
24	Cardio	logy clinical and academic group
25	St Geo	rge's, University of London, and St George's University Hospital NHS
26	Found	ation Trust.
27	Cranm	er Terrace, London SW17 0RE, UK
28 NO	⊤E:-mail	epant hepons and should not be used to guide clinical practice.

29 ABSTRACT

30 BACKGROUND:

Studies in ostensibly healthy male master athletes have revealed a greater prevalence of coronary artery calcification (CAC) and coronary plaques compared with relatively sedentary counterparts. In contrast, data relating to potentially adverse coronary remodelling in female master athletes is sparse and conflicting. We investigated the prevalence of coronary atherosclerosis in a cohort of predominantly post-menopausal female master athletes with a low atherosclerotic risk profile.

37

38 METHODS:

196 female athletes with a mean age of 55±7 years-old and median exercise duration of 33 years (25-39) and 59 relatively sedentary females of similar age underwent cardiovascular investigations including a coronary computed tomogram angiography with assessment of CAC scores, coronary plaques, and pericoronary adipose tissue attenuation. 70% of the athletes and 68% of the control group were postmenopausal.

45

46 **RESULTS:**

Athletes and controls had a similarly low Framingham 10-year risk (1.49% versus
2.1%; P=0.68), but body mass index and blood pressure were lower and HDL-C was
higher in the athletes. The prevalence of CAC score >0 Agatston units (AU) was low
and did not differ between athletes and controls (21% versus 32%;P=0.073). Female

athletes had a lower prevalence of a CAC score >50th centile (19% versus 51 32%;P<0.03) and >75th centile (14% versus 25%;P=0.045) for age compared with 52 controls, but the prevalence of a CAC score >100 AU did not differ between the 53 groups (3.6% versus 8.5%;P=0.12). There were also no differences between the 54 groups in the prevalence of individuals with coronary plaques (21% versus 55 32%;P=0.09), total plaque volume (16 mm³ [IQR 3-56] versus 49 [5-142] 56 mm³;P=0.08), or plaque burden (10.8% [2.8-21] versus 15.4% [4.6-28];P=0.46). 57 Coronary plagues were predominantly calcified in both athletes and controls (80% 58 versus 63%;P=0.08). Age, blood pressure and HDL-C were independent predictors for 59 a CAC score >0 AU among athletes. 60

61

62 **CONCLUSIONS:**

In contrast with previous studies in male master athletes, lifelong exercise in female counterparts does not appear to be associated with increased CAC score, coronary plaque burden or any qualitative differences in coronary plaque compared with relatively sedentary healthy counterparts. Coronary atherosclerosis in master female athletes is mainly driven by traditional risk factors.

68 Word count 343

69 Introduction

70 The benefits of exercise for curbing risk factors for atherosclerosis and reducing overall cardiovascular morbidity and mortality are widely recognized^{1,2}, however, 71 several studies have shown an increased burden of coronary atherosclerosis in male 72 master athletes³⁻⁶. Whereas original studies reported increased coronary artery 73 74 calcification (CAC) in male marathon runners with a relatively high prevalence of atherosclerotic risk factors⁴, recent studies have shown similar findings in male 75 master athletes with a low atherosclerotic risk profile ^{3,5,6}. Increasing age, traditional 76 risk factors and volume of exercise are major determinants of high CAC scores in 77 78 males although coronary inflammation, dietary factors, blood pressure responses to exercise and serum parathyroid hormone concentrations have also been 79 postulated⁷⁻⁹. Over the past couple of decades, there has been an explosive surge in 80 the number of middle-aged and older women participating and excelling in mass 81 82 endurance sporting events and competitive races, however there are few studies examining the effect of lifelong exercise on the coronary vasculature in women. 83 Existing reports are conflicting $^{6,10-12}$ and limited by the small number of participants, 84 variation in the prevalence of atherosclerotic risk factors between the comparison 85 groups and inclusion of mainly premenopausal or perimenopausal women who may 86 be protected by the anti-atherogenic effects of estrogen. 87

88 We investigated the prevalence, magnitude and determinants of CAC score and 89 coronary plaque in predominantly post-menopausal female master athletes with a 90 low atherosclerotic risk profile.

91

92 METHODS

93 Subjects:

Female master athletes were defined as athletes aged ≥40 years-old who had 94 exercised systematically and continuously for ≥ 10 years and had competed in ≥ 10 95 endurance events. Athletes were recruited by contacting governing sporting bodies 96 for master athletes including the British Master Athletics Federation, British Master 97 Swimming Association, Master Rowing, British triathlon and several endurance 98 99 sports clubs in London, United Kingdom. Healthy controls were recruited through 100 advertisements in 3 London National Heart Service Trusts and advertisements in community centers. Controls were of similar age and allowed to engage in up to 3 101 hours of moderate intensity physical activity and recreational exercise per week. 102 Athletes or controls with a history of coronary artery disease (CAD), hypertension, 103 diabetes mellitus, a Framingham 10-year risk score >10%, a family history of 104 105 premature CAD (<65 years in female relatives or <55 years in male relatives), current 106 or previous history of smoking, and contraindications to coronary computed tomography angiography (CCTA), or cardiovascular magnetic resonance (CMR) were 107 108 excluded. Between 02/2017 and 09/2018 196 athletes and 59 sedentary controls underwent a battery of investigations including a health questionnaire, blood tests, 109 ECG, echocardiogram, cardiopulmonary exercise test (CPET), coronary computed 110 111 tomography angiogram (CCTA) and cardiovascular magnetic resonance (CMR) scan. 112 Participants attended on 3 separate days to complete these investigations. The first 113 attendance included a health questionnaire, blood tests and CPET. The second and

third attendances involved a CCTA and CMR respectively. The time span forcompleting all these investigations per participant was 4-6 weeks.

116

117 Health questionnaire:

Participants completed a baseline questionnaire (supplement 1) enquiring about demographics, cardiac symptoms, medical history, smoking history, family history of cardiac disease, menstrual history including age at menopause, if applicable, and exercise history. Menopause was considered if a woman had not menstruated for ≥ 12 months.

123

124 **Exercise history and intensity:**

The exercise history focused on the duration and intensity of exercise, including total 125 number of years of exercise, sports discipline(s), total number of competitions in 126 sporting events, best times achieved in competitions, and major achievements. The 127 intensity of exercise was assessed through the International Physical Activity 128 129 Questionnaire (IPAQ) which is a widely used, standardized, and validated questionnaire^{13,14} (supplement 2). The weekly dose of exercise was estimated by 130 calculating the metabolic equivalent of task (MET) minutes per week from the 131 information ascertained by the IPAQ. 132

133

134 Blood investigations:

Blood samples were analyzed for serum lipid profile, blood glucose and renal function. A separate blood sample was also taken 15 minutes after the completion of the cardiopulmonary exercise test for assessment of parathyroid hormone (PTH) concentrations, with values > 6.9 pmol/L to be considered as increased (laboratory reference range 1.1 - 6.9 pmol/L).

140

141 Cardiopulmonary exercise test:

142 Cardio-pulmonary exercise testing was performed in an upright position using a 143 COSMED E100w cycle ergometer (Rome, Italy) with an incremental ramp protocol of 20-25 Watts/min for athletes and 10-15 Watts/min for healthy controls and 144 simultaneous continuous ECG recording. Subjects were encouraged to exercise to 145 the point of exhaustion. Breath-by-breath gas exchange analysis was performed 146 using a dedicated COSMED Quark CPEX metabolic cart (Rome, Italy) and standard 147 cardiometabolic indices were obtained according to published guidelines¹⁵. Blood 148 149 pressure was manually obtained at rest and at 2-minute intervals during exercise. Exercise induced hypertension was defined as systolic blood pressure of \geq 190mmHg 150 during exercise^{22,23}. 151

152

153 Cardiac Investigations:

Coronary computed tomography angiography (CCTA). CCTA was performed using a 64 slice LightSpeed VCT XTe GE scanner (GE Healthcare) and prospective gating, using a commercially available protocol (SnapShot Pulse, GE healthcare) and the following scanning parameters: slice acquisition 64 x 0.625 mm, smallest X-ray

window, Z-coverage value of 20 mm with an increment of 20 mm, gantry rotation 158 159 time of 350 ms. Some participants received intravenously Metoprolol (5-20mg) to achieve a heart rate ≤60 bpm. All volunteers received two 400 mcg doses of 160 sublingual Glyceryl trinitrate. The coronary circulation was visualized by injecting 100 161 ml of intravenous Ivoersol (Optiray 350 mg I/ml, Covidien UK, Hampshire, UK) at a 162 flow rate of 5 ml/s followed by 100 ml of saline solution into an antecubital vein via 163 an 18-gauge peripheral venous catheter. All images were transferred to an external 164 workstation (Autoplague, v2.18.08.23, Mount Sinai, USA) for analysis. Plague 165 quantification analysis was performed in 35 athletes and 10 controls. A semi-166 automated 3D quantification and characterization of segments with plaque on CCTA 167 was used to define the plaque composition, total plaque volume and total plaque 168 169 burden as validated previously^{16,17}. Plague prevalence was defined as the number of 170 individuals with plaques. Plaque burden was defined as the respective plaque volume/vessel volume. Plaque morphology was sub-divided into calcified, mixed 171 morphology or non-calcified plaque and plaque composition was defined as plaque 172 morphology/total plaque volume. Pathological CAD was defined as the presence of 173 ≥1 of the following (a) CAC score >100 Agatston Units (AU), (b) CAC score >75% for 174 175 age, or (c) vessel stenosis>50%.

176

177 Pericoronary Adipose Tissue (PCAT):

PCAT CT attenuation was used to assess coronary inflammation based on previously described and validated methodology^{18–20}. PCAT was defined as the adipose tissue within a radial distance from the outer vessel wall equal to the diameter of the

vessel. Quantification was based on the attenuation histogram of perivascular fat 181 within the range –190 Hounsfield Units (HU) to –30 HU. The proximal right coronary 182 artery (RCA) was used for PCAT analysis. The proximal 10-50mm of the RCA were 183 analyzed excluding the first 10mm. PCAT CT attenuation derived values were 184 normalized for the kilovoltage peak (KVP) potential. The mean PCAT CT attenuation 185 was determined in a 1 mm cylinder within a radial distance from the outer vessel 186 187 wall equal to the average diameter of the right coronary artery (FAI_{RCA}). FAI analysis 188 was performed in 151 female athletes and 36 controls.

189

190 Cardiovascular Magnetic Resonance (CMR) Scan:

191 Participants underwent CMR using a 1.5T magnet (Aera, Siemens Medical Solutions) as described previously⁶. Chamber volumes, myocardial mass, ventricular function, 192 and aortic dimensions were assessed by cine steady-state free precession 193 sequences²¹. Delayed contrast enhancement images were obtained 15 min after 194 195 intravenous bolus injection of gadolinium-diethylene triamine pentaacetic acid (Gd-DTPA) (0.15 mmol/kg, Magnevist, Bayer Healthcare Pharmaceuticals, New Jersey, 196 USA) to identify regional fibrosis. Inversion times were adjusted to null normal 197 myocardium and late gadolinium enhancement (LGE) images were phase swapped 198 to exclude artefacts. 199

200

201 Statistical Analysis.

202 Data are expressed as n (%), mean ± standard deviation (SD) for normally distributed 203 continuous variables, or as median plus 25th-75th interguartile percentiles for

204 continuous variables that are not normally distributed. Statistical analyses were 205 performed using Stata/IC version 15.1. Continuous variables were tested for 206 normality using a Shapiro-Wilk test. Chi-squared and Fischer's exact tests were used 207 for the comparison of categorical variables while unpaired t-tests and Mann-Whitney 208 U tests were used for normally and non-normally distributed variables respectively.

209 Among master athletes, univariate logistic regression was performed to identify statistically significant variables associated with CAC score >0 and FAI. We decided a 210 211 priori to include age, years of exercise, competitions completed, MET mins of exercise per week, menopausal status, resting systolic blood pressure (SBP), maximal 212 SBP during exercise, total cholesterol, HDL cholesterol, parathyroid hormone (PTH) 213 214 levels, left ventricular mass, and peak VO₂. Coronary inflammation (FAI_{RCA}) was 215 subsequently added to the CAC score >0 model. A backward stepwise multivariable logistic regression model was constructed retaining all variables with associated with 216 217 CAC score >0 or FAl_{RCA} (P<0.10) in the univariable analyses. A P-value <0.05 was 218 considered statistically significant.

219

220 RESULTS

221 Demographics and atherosclerotic risk profile

A total of 196 master athletes and 59 controls fulfilled criteria for participation. Athletes and controls were of similar age and had a similarly low mean Framingham risk and post-exercise PTH concentrations. There were no significant differences between athletes and controls with respect to the proportion of post-menopausal women. Controls were heavier than athletes, which translated to a modestly greater

body surface area. Controls also revealed higher systolic and diastolic blood pressure
readings, whereas athletes had a slightly higher mean total and HDL cholesterol
compared with controls. Athletes revealed higher peak oxygen consumption than
controls and almost a quarter of the athletes showed an exaggerated blood pressure
during exercise (SBP>190 mm Hg at peak exercise) compared with 10% of the control
group (p<0.001) (Table 1).

233

234 Exercise history:

235 Among athletes, endurance competitions included marathons (26.2miles; 42.2km), 236 half marathons (13.1miles; 21.1km), 10km running races, endurance cycling races ranging from 41.1 miles to 161.5 miles; 66 to 260 km), triathlons, rowing regattas, 237 marathons, or river races. Master athletes had been exercising for a median of 33 238 239 years and trained for an average of 8 hours per week. Forty-five athletes were UK 240 Master champions, 27 were European Master champions or finalists, 16 were World 241 Master champions, and 2 were former Olympic medalists. Most athletes engaged in 242 running (n=144, 73%), followed by cycling (n=91, 46%), swimming (n=82, 41%) and rowing (n=22, 11%). 243

244

245 Coronary calcium score:

The prevalence of CAC score >0 was low and did not differ between athletes and controls (21% versus 32%: P=0.073) (**Table 2**). There were no significant differences between the groups with respect to the prevalence of CAC score >100. Female athletes showed a lower prevalence of CAC score >50% centile (19% versus 32%;

P=0.03) and CAC score >75% centile (14% versus 25%; P=0.045) compared with controls (**Figure 1**). Athletes were also less likely to exhibit pathological CAD (CAC score >100, or >75th percentile for age) compared with controls (15% versus 25%; P=0.045).

254

255 Coronary plaques and luminal irregularities:

Both athletes and controls had a low prevalence of atherosclerotic plagues (21% 256 versus 32%; P=0.09). Athletes and controls did not differ in the prevalence or 257 distribution of the atherosclerotic plaques (Figure 2, Table 2). Coronary plaques 258 were predominantly located in the proximal and mid portion of the left anterior 259 descending athletes among athletes and non-athletes. None of the female athletes 260 or controls revealed obstructive CAD (luminal stenosis >50%), but 6 (3%) athletes 261 and 4 (7%) controls had mild stenosis (25-49%) (Table 2). Coronary plagues were 262 predominantly calcified in both athletes and controls (80% versus 63%; P=0.08) 263 264 although athletes had a lower prevalence of mixed morphology plaques (Figure 2b).

265 **Coronary plaque volume, burden, and composition and coronary inflammation:**

Quantitative analysis revealed no differences in total, calcified, low density calcified, and non-calcified plaque volumes between the two groups (**Figure 3**, **Table 3**) In contrast, a higher burden of calcified plaque was observed in controls.

The level of coronary inflammation as derived by FAI_{RCA} was significantly higher (less negative) in female athletes compared with controls (-64 ± 7.9 HU versus -69 ± 8.4 HU, P=0.002 (Table 3; Figure 4a). Subgroup analysis revealed that FAI_{RCA} was

significantly higher (more inflammation) in athletes with CAC score =0 compared to those with a CAC score >0) (-62.9 \pm 7.3 versus -66.0 \pm 8.8 HU; P=0.024) and compared to controls with a CAC score=0 (-62.9 \pm 7.3 versus -68.2 \pm 8.1 HU; P=0.001) (**Figure 4b**).

276

277 Determinants of coronary atherosclerosis:

Univariate analysis revealed that age, years of exercise, absolute peak VO2, resting 278 279 systolic blood pressure, lower coronary inflammation (FAI_{RCA}) and lower values of 280 HDL-C, were associated with an increased probability of a CAC score>0. Multivariate logistic regression showed a positive association between age and CAC score> 0 (OR: 281 1.14 per year; 95% CI: 1.07–1.21); p<0.001] and resting SBP (OR: 1.03 per mmHg; 282 95% CI: 1.008–1.06); p=0.012] and an inverse association with HDL-C (OR: 0.34 per 283 284 mol/L, 95% CI: 0.15-0.79; p=0.011) (Table 4). Among athletes, markers of coronary atherosclerosis were found in most women aged >65 years old (n=18) with 78% 285 showing evidence of coronary plaque(s), 22% demonstrating a CAC score >100 AU 286 and 11% revealing a CAC score >400 AU. Indeed, a CAC score >100 AU was almost 287 288 confined to women aged \geq 65 years old (**Figure 5**).

289 **Determinants of coronary inflammation:**

A higher degree of coronary inflammation was associated with, years of exercise, peak VO2, a lower BMI and lower age and a higher HDL. Multivariate linear regression identified a positive correlation (R^2 =0.19) between inflammation and peak

293 VO₂ (beta 0.44 per ml/min/kg 95% CI 0.24- 0.64; p<0.01) and HDL (beta 1.4 per
294 mmol/L 95% CI 0.10- 2.7; p<0.05).

295

296 Myocardial scar:

Five athletes had major scar within the left ventricular myocardium including 2 with an ischaemic pattern (one with a small area of subendocardial basal inferolateral scar and the other with a small area of focal transmural basal inferior scar) and 3 athletes with non-ischaemic scar affecting the mid portion of the lateral LV wall. Neither of the 2 athletes with ischaemic scar revealed any evidence of CAD on CCTA.

302

303 DISCUSSION

There are few existing studies reporting coronary atherosclerosis in master female athletes with a cumulative total of <100 athletes^{6,10–12}. Based on the relatively small numbers and contradictory conclusions in these small studies, it is difficult to infer whether increased CAC and plaque burden observed in some female athletes reflects advanced age, cumulative effects of prodigious exercise, or other factors.

In the current study, we investigated the prevalence of markers of coronary atherosclerosis in 196 female master athletes and 59 ostensibly healthy and relatively sedentary women who were predominantly post-menopausal and had a low atherosclerotic risk profile. Despite a significantly larger cohort of athletes, we did not observe any differences in CAC score, number of coronary plaques, plaque volume or the morphology of the coronary plaques between the two groups. Both

athletes (21%) and controls (32%) had a low prevalence of CAD, although athletes were less likely to have a CAC score $>50^{th}$ and 75^{th} percentile for age. Age was the most important determinant of an elevated CAC score and most females with markers of coronary atherosclerosis were aged ≥ 65 years old.

319

320 **Predictors of coronary atherosclerosis:**

Exercise duration and volume have been associated with CCTA markers of 321 322 atherosclerosis in male athletes³, however we did not observe any significant 323 association with the exercise history and CAC score even though our female athletes had exercised for a median of 33 years and participated in a median of 90 endurance 324 events, which is comparable with previous studies in male athletes with raised CAC 325 score^{3,4,6}. Several mechanisms have been implicated for the increased coronary 326 atherosclerosis in male master athletes^{7,8,22}, including damage from mechanical 327 328 stresses of bending and flexing of the coronary arteries, increased LV mass, exerciseinduced hypertension²³, post-exertional increased parathyroid levels^{24,25} and 329 coronary inflammation²⁶. We observed a SBP>190mmHg during exercise in a quarter 330 of our athletes, but could not reveal any association with CAD. Similarly, exercise-331 induced elevations of PTH concentrations were observed, but the magnitude of 332 these changes were equal in athletes and controls and did not correlate with 333 coronary calcification. In contrast, traditional risk factors such as age, resting blood 334 335 pressure and lipid profile influenced CAC score in female athletes. As opposed to previous studies in master male athletes, we could not demonstrate any association 336 between the duration and volume of exercise and an elevated CAC^{3,27}. 337

338

339 **Coronary Inflammation:**

340 Several studies have indicated that there may be a threshold beyond which highintensity endurance exercise can cause increased oxidative stress and reduced levels 341 of anti-oxidants^{28,29}. Schwarz et al revealed an acute and transient increase in post-342 343 race apoptotic endothelial microparticles in 99 middle-aged marathon runners, including 22% females, indicating that high intensity exercise may be linked to 344 endothelial cell damage and a pro-inflammatory response³⁰. Lin *et al*²⁶ investigated 345 coronary artery plaque characteristics before and after completion of a 140-day race 346 entailing 25.7 miles/day with one rest day per week. Among the 4 runners with prior 347 CAD, there was an increase in non-calcified plaque volume at sites of pre-existing 348 349 disease, whereas there was no evidence of *de novo* plaque in the remaining 5 runners. These observations suggest that extreme endurance exercise may stimulate 350 351 CAD progression independent of traditional atherosclerotic factors, through mechanisms including inflammation. We revealed an increased prevalence of 352 coronary inflammation in our female athletes compared with controls, however this 353 was not a determinant or associated with a raised CAC score. Conversely, there 354 appeared to be an inverse trend between inflammation in athletes with a normal 355 CAC score versus athletes with an abnormal CAC score. It should be noted, however, 356 357 that most female athletes in our cohort had a zero CAC score and individuals with 358 conventional risk markers for endothelial damage had been excluded from the study.

359 Sex disparities:

Our data suggest that there is sex-specific coronary artery remodeling in master 360 361 athletes. Whereas our previous experience in male athletes has shown a higher prevalence of high CAC (>100 AU) and increased prevalence of coronary plaques 362 compared with healthy controls ^{7–9} we did not observe similar results in our female 363 master athletes. In contrast, female master athletes were less likely to have a 364 CAC>50th and 75th centile and mixed morphology plaques compared with healthy 365 non athletes. Age was the most important determinant of CAD. Although older 366 female athletes (>65-years-old) showed a higher prevalence of CAC score>0 and 367 plaque burden compared with younger women, we observed exclusively non-368 obstructive CAD in all age categories compared with previous reports of significant 369 stenoses (>50%) in 6-8% males^{6,27}. Sex-specific characteristics including hormonal 370 ^{31,32}, hemodynamic, anthropometric, and psychological factors may be protective in 371 372 female master athletes compared with male athletes.

Despite the lack of correlation between previously speculated associations between exercise and markers of coronary atherosclerosis on CCTA among our female athletes, we identified ischaemic scar in two athletes who had no evidence of CAD, suggesting that there may be other mechanisms for limited infarction, such as coronary spasm, demand ischaemia or spontaneous occlusion of micro vessels due to a prothrombotic state although our numbers are too small to make any strong inferences.

380

381 Limitations:

Our study has several limitations. We relied solely on subjective assessment for menstrual status rather than endocrine profiles, therefore we cannot be certain how far our results were affected by circulating estrogen concentrations. We did not investigate the effect of dietary habits or genetic predisposition in the development of atherosclerosis in our athletes. Most of our athletes were white, and all were involved in endurance sports therefore it is uncertain whether these results can be extrapolated in athletes of different ethnicity or sports disciplines.

389

390 CONCLUSION

391 In contrast with previous experience in male master endurance athletes, female counterparts do not reveal increased CAC scores or plaque burden compared with 392 relatively sedentary healthy women. Among the small number of female athletes 393 with increased CAC scores, age, blood pressure and lipid profile were the most 394 395 important determinants of coronary atherosclerosis rather than the volume, 396 duration and intensity of exercise. Larger studies in even older master female athletes may help delineate sex related differences in coronary artery remodeling in 397 398 lifelong endurance athletes more precisely.

399

400 Acknowledgements:

401 The authors would like to acknowledge 1. Dr Sarojini David for assisting and 402 interpreting the coronary computed tomography angiograms. 2. Paulo Bulleros and

403 Zephryn Fanton for assistance with transthoracic echocardiography and

404 cardiopulmonary exercise tests.

405

```
406 Funding
```

- 407 Dr Efstathios Papatheodorou was funded by a research grant provided by the
- 408 charitable organisation Cardiac Risk in the Young (CRY).

409 Disclosures

410 None of the authors have any conflicts to declare.

411 References

- 412 1. Lavie CJ, Arena R, Swift DL, Johannsen NM, Sui X, Lee DC, Earnest CP, Church TS, 413 O'Keefe JH, Milani R V, Blair SN. Exercise and the cardiovascular system: Clinical 414 science and cardiovascular outcomes. Circ Res. 2015;117:207-219.
- 415 2. Lee IM, Shiroma EJ, Lobelo F, Puska P, Blair SN, Katzmarzyk PT, Alkandari JR, 416 Andersen LB, Bauman AE, Brownson RC, Bull FC, Craig CL, Ekelund U, Goenka S, 417 Guthold R, Hallal PC, Haskell WL, Heath GW, Inoue S, Kahlmeier S, Kohl HW, Lambert 418 EV, Leetongin G, Loos RJF, Marcus B, Martin BW, Owen N, Parra DC, Pratt M, Ogilvie 419 D, Reis RS, Sallis JF, Sarmiento OL, Wells JC. Effect of physical inactivity on major non-420 communicable diseases worldwide: An analysis of burden of disease and life expectancy. The Lancet. 2012;380:219-229. 421
- 422 3. Aengevaeren VL, Mosterd A, Braber TL, Prakken NHJ, Doevendans PA, Grobbee DE, 423 Thompson PD, Eijsvogels TMH, Velthuis BK. The Relationship Between Lifelong Exercise Volume and Coronary Atherosclerosis in Athletes. Circulation. 2017; 424
- 425 Mohlenkamp S, Lehmann N, Breuckmann F, Brocker-Preuss M, Nassenstein K, Halle 4. 426 M, Budde T, Mann K, Barkhausen J, Heusch G, Jockel K-H, Erbel R. Running: the risk of 427 coronary events : Prevalence and prognostic relevance of coronary atherosclerosis in 428 marathon runners. Eur Heart J. 2008;29:1903–1910.
- 429 5. De Bosscher R, Dausin C, Claus P, Bogaert J, Dymarkowski S, Goetschalckx K, Ghekiere O, Van De Heyning CM, Van Herck P, Paelinck B, El Addouli H, La Gerche A, Herbots L, 430 431 Willems R, Heidbuchel H, Claessen G, Van Soest S, Claeys M, Hespel P, Dresselaers T, 432 Miljoen H, Belmans A, Favere K, Vermeulen D, Witvrouwen I, Hansen D, Eijnde BO, 433 Thijs D, Vanvoorden P. Lifelong endurance exercise and its relation with coronary 434 atherosclerosis. Eur Heart J. 2023;
- 435 Merghani A, Maestrini V, Rosmini S, Cox AT, Dhutia H, Bastiaenan R, David S, Yeo TJ, 6. Narain R, Malhotra A, Papadakis M, Wilson MG, Tome M, Alfakih K, Moon JC, Sharma 436 S. Prevalence of Subclinical Coronary Artery Disease in Masters Endurance Athletes 437 438 with a Low Atherosclerotic Risk Profile. Circulation [Internet]. 2017;136:126–137. 439 Available from: http://ahajournals.org
- 440 7. Aengevaeren VL, Mosterd A, Sharma S, Prakken NHJ, Möhlenkamp S, Thompson PD, 441 Velthuis BK, Eijsvogels TMH. Exercise and Coronary Atherosclerosis. Circulation. 442 2020;141:1338-1350.
- 443 8. Parry-Williams G, Sharma S. The effects of endurance exercise on the heart: panacea or poison? Nat Rev Cardiol. 2020;17:402-412. 444
- 445 9. Sharma S, Merghani A, Mont L. Exercise and the heart: the good, the bad, and the 446 ugly. Eur Heart J. 2015;36:1445–1453.
- Bachman NP, Terwoord JD, Richards JC, Braun B, Green CP, Luckasen GJ, Dinenno FA. 447 10. 448 Comprehensive assessment of cardiovascular structure and function and disease risk 449 in middle-aged ultra-endurance athletes. Atherosclerosis. 2021;320:105–111.
- 450 11. Roberts WO, Schwartz RS, Kraus SM, Schwartz JG, Peichel G, Garberich RF, Lesser JR, 451 Oesterle SN, Wickstrom KK, Knickelbine T, Harris KM. Long-Term Marathon Running

452 Is Associated with Low Coronary Plague Formation in Women. Med Sci Sports Exerc. 453 2017;49:641-645. 454 12. Jafar O, Friedman J, Bogdanowicz I, Muneer A, Thompson PD, Ling J, Messina A, Yen 455 M, Wakefield D, Varanasi P, Haleem K. Assessment of Coronary Atherosclerosis Using Calcium Scores in Short- and Long-Distance Runners. Mayo Clin Proc Innov Qual 456 457 Outcomes. 2019;3:116-121. 458 13. Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML, Ainsworth BE, Pratt M, 459 Ekelund U, Yngve A, Sallis JF, Oja P. International physical activity questionnaire: 12-460 Country reliability and validity. *Med Sci Sports Exerc*. 2003;35:1381–1395. Kurtze N, Rangul V, Hustvedt BE. Reliability and validity of the international physical 461 14. 462 activity questionnaire in the Nord-Trøndelag health study (HUNT) population of men. 463 BMC Med Res Methodol [Internet]. 2008 [cited 2023 Nov 16];8:63. Available from: 464 /pmc/articles/PMC2577099/ 465 15. Sharma S, Elliott PM, Whyte G, Mahon N, Virdee MS, Mist B, McKenna WJ. Utility of 466 metabolic exercise testing in distinguishing hypertrophic cardiomyopathy from 467 physiologic left ventricular hypertrophy in athletes. J Am Coll Cardiol. 2000;36:864– 870. 468 469 16. Dey D, Cheng VY, Slomka PJ, Nakazato R, Ramesh A, Gurudevan S, Germano G, 470 Berman DS. Automated 3-dimensional quantification of noncalcified and calcified 471 coronary plaque from coronary CT angiography. J Cardiovasc Comput Tomogr. 472 2009;3:372-382. 473 17. Dey D, Schepis T, Marwan M, Slomka PJ, Berman DS, Achenbach S. Automated three-474 dimensional guantification of noncalcified coronary plague from coronary CT 475 angiography: Comparison with intravascular US. Radiology. 2010;257:516–522. 476 18. Oikonomou EK, Marwan M, Desai MY, Mancio J, Alashi A, Hutt Centeno E, Thomas S, Herdman L, Kotanidis CP, Thomas KE, Griffin BP, Flamm SD, Antonopoulos AS, 477 Shirodaria C, Sabharwal N, Deanfield J, Neubauer S, Hopewell JC, Channon KM, 478 479 Achenbach S, Antoniades C. Non-invasive detection of coronary inflammation using 480 computed tomography and prediction of residual cardiovascular risk (the CRISP CT 481 study): a post-hoc analysis of prospective outcome data. Lancet. 2018;392:929–939. 482 19. Antonopoulos AS, Sanna F, Sabharwal N, Thomas S, Oikonomou EK, Herdman L, 483 Margaritis M, Shirodaria C, Kampoli A-M, Akoumianakis I, Petrou M, Sayeed R, Krasopoulos G, Psarros C, Ciccone P, Brophy CM, Digby J, Kelion A, Uberoi R, Anthony 484 485 S, Alexopoulos N, Tousoulis D, Achenbach S, Neubauer S, Channon KM, Antoniades C. 486 Detecting human coronary inflammation by imaging perivascular fat. Sci Transl Med. 487 2017;9:eaal2658. 488 20. Goeller M, Achenbach S, Cadet S, Kwan AC, Commandeur F, Slomka PJ, Gransar H, 489 Albrecht MH, Tamarappoo BK, Berman DS, Marwan M, Dey D. Pericoronary Adipose 490 Tissue Computed Tomography Attenuation and High-Risk Plaque Characteristics in 491 Acute Coronary Syndrome Compared With Stable Coronary Artery Disease. JAMA 492 Cardiol. 2018;3:858.

por	polulty.		
It is made available under a	CC-BY 4.0) International	license.

493 494 495	21.	Bhuva AN, D'Silva A, Torlasco C, Jones S, Nadarajan N, Van Zalen J, Chaturvedi N, Lloyd G, Sharma S, Moon JC, Hughes AD, Manisty CH. Training for a First-Time Marathon Reverses Age-Related Aortic Stiffening. <i>J Am Coll Cardiol</i> . 2020;75:60–71.
496	22.	Merghani A, Sharma S. The veteran athlete's heart. Eur Heart J. 2015;36:954–955.
497 498 499	23.	Kim CH, Park Y, Chun MY, Kim YJ. Exercise-induced hypertension can increase the prevalence of coronary artery plaque among middle-aged male marathon runners. <i>Medicine</i> . 2020;99:e19911.
500 501 502	24.	Bouassida A, Latiri I, Bouassida S, Zalleg D, Zaouali M, Feki Y, Gharbi N, Zbidi A, Tabka Z. Parathyroid hormone and physical exercise: A brief review. J Sports Sci Med. 2006;5:367–374.
503 504	25.	Kamycheva E, Sundsfjord J, Jorde R. Serum parathyroid hormone levels predict coronary heart disease: The TromsãfÂ, Study. <i>Eur J Prev Cardiol</i> . 2004;11:69–74.
505 506 507	26.	Lin J, DeLuca JR, Lu MT, Ruehm SG, Dudum R, Choi B, Lieberman DE, Hoffman U, Baggish AL. Extreme Endurance Exercise and Progressive Coronary Artery Disease. <i>J</i> <i>Am Coll Cardiol</i> . 2017;70:293–295.
508 509 510 511	27.	Aengevaeren VL, Mosterd A, Bakker EA, Braber TL, Nathoe HM, Sharma S, Thompson PD, Velthuis BK, Eijsvogels TMH. Exercise Volume Versus Intensity and the Progression of Coronary Atherosclerosis in Middle-Aged and Older Athletes: Findings from the MARC-2 Study. <i>Circulation</i> . 2023;147:993–1003.
512 513 514 515	28.	Bergholm R, Mäkimattila S, Valkonen M, Liu ML, Lahdenperä S, Taskinen MR, Sovijärvi A, Malmberg P, Yki-Järvinen H. Intense physical training decreases circulating antioxidants and endothelium-dependent vasodilatation in vivo. <i>Atherosclerosis</i> . 1999;145:341–349.
516 517 518 519	29.	Goto C, Higashi Y, Kimura M, Noma K, Hara K, Nakagawa K, Kawamura M, Chayama K, Yoshizumi M, Nara I. Effect of different intensities of exercise on endothelium- dependent vasodilation in humans: Role of endothelium-dependent nitric oxide and oxidative stress. <i>Circulation</i> . 2003;108:530–535.
520 521 522 523	30.	Schwarz V, Düsing P, Liman T, Werner C, Herm J, Bachelier K, Krüll M, Brechtel L, Jungehulsing GJ, Haverkamp W, Böhm M, Endres M, Haeusler KG, Laufs U. Marathon running increases circulating endothelial- and thrombocyte-derived microparticles. <i>Eur J Prev Cardiol</i> . 2018;25:317–324.
524 525	31.	Barrett-Connor E, Bush TL. Estrogen and Coronary Heart Disease in Women. JAMA: The Journal of the American Medical Association. 1991;265:1861–1867.
526 527 528	32.	Versi E, Collins P, Stevenson JC, Godsland IF, Riedel M, Mügge A. Oestrogen and protection against myocardial ischaemia [Internet]. The Lancet. 1993;342:871–872. Available from: http://www.thelancet.com/article/014067369392733A/fulltext
529		
530		

- 531 Table 1 Baseline demographics, atherosclerotic risk profile characteristics, exercise
- history and imaging characteristics of female master athletes and sedentary controls. 532

	Female Athletes	Controls	p value
	N=196	N=59	
Age (years)	54.8 ± 7.4	54 ± 6.4	0.99
Height (cm)	166.4 ± 6.4	163.7 ± 7.4	<0.01
Weight (kg)	59 ± 8.1	66 ± 6	<0.01
BMI (kg/m ²)	21.4 ± 4.1	24 ± 5.5	<0.01
White Caucasian n (%)	180 (92)	55 (93)	0.92
Risk factors for CAD			
Systolic BP (mm Hg)	115 ± 6.6	124 ± 6.9	<0.01
Diastolic BP (mm Hg)	74.3 ± 7.6	78.3 ± 7.8	<0.01
Total Cholesterol (mmol/L)	5.0 ± 0.5	4.8 ± 0.6	<0.01
HDL-C (mmol/L)	2.4 ± 0.3	1.9± 0.3	<0.01
Menopausal n (%)	139 (71)	40 (68)	0.85
Framingham 10-year risk score	1.5 ± 0.6	2.1 ± 0.7	0.09
Exercise History			
Years of Exercise	33 (25 - 39)	2 (0 - 1)	<0.01
Hours of exercise per week	8 (6 - 10)	0 (0 - 1)	<0.01
Days of exercise per week	6 (4 - 6)	0 (0 - 2)	<0.01
Total Competitions	90 (15 - 134)	0 (0 - 0)	<0.01
METS minutes per week	7225 (4784 –	233 (120-919)	<0.01
	10647)		
Vigorous METS minutes per week	2880 (2160 –	0 (0 - 280)	<0.01
	4800)		
CPET and CMR parameters			
Peak VO2 (ml/min/kg)	42 ± 4.6	25 ± 7.3	<0.01
PeakVO2 predicted (%)	163.5 ± 24.6	104.8 ± 19.9	<0.01
Exercise induced HTN n (%)	48 (25%)	6 (10%)	<0.01
Post exertional PTH levels (pmol/l)	7.84 ± 2.5	8.3 ± 2.4	0.40

It is made available	under a CC-BY	Y 4.0 International li	cense .

Raised post-exertional PTH n (%)	114 (58)	35 (57)	0.91
LVEDV (ml)	137 ± 23	121 ± 21	<0.01
LVEDV/BSA (ml/mm ²)	82 ± 12	69 ± 8	<0.01
RVEDV (ml)	132 ± 26	124 ± 27	<0.01
RVEDV/BSA (ml/mm ²)	80 ± 14	69 ± 10	<0.01
Left Ventricular Mass (g)	129.5 ± 32	112 ± 25.5	<0.01
RV insertion point fibrosis n (%)	62 (32)	5 (8)	<0.01
Ischemic LGE	2 (1%)	0 (0%)	0.54

BP=Blood Pressure; CAD=Coronary Artery Disease; CMR=Cardiovascular magnetic
resonance; CPET=Cardiopulmonary exercise test; HDL-C=High-Density Lipoprotein
Cholesterol; HTN=Hypertension; LGE= Late Gadolinium Enhancement; LVEDV = LV
End-diastolic Volume; METS=Metabolic Equivalents; PTH=parathyroid hormone;
RVEDV = RV End-diastolic Volume; SD = Standard Deviation; VO2 = Oxygen
Consumption. Values are presented as mean ± SD, n (%), or median (Interquartile
25%-75%).

543 Table 2. Comparison of CAC score, plaque prevalence, distribution and coronary

inflammation in female master athletes and sedentary controls. Expressed as n (%) 544

	Athletes	Controls	p-value
	n=196	n=59	
Median CACS (AU)	0 (0 - 0)	0 (0 - 7)	0.08
CACS > 0 AU	41 (21%)	19 (32%)	0.07
CACS > 100 AU	7 (3.6%)	5 (8.5%)	0.12
CACS > 400 AU	2 (1%)	2 (3%)	0.20
CACS centile >50%	37 (19%)	19 (32%)	0.03
CACS centile >75%	28 (14%)	15 (25%)	0.045
Individuals with	42 (21%)	19 (32%)	0.09
≥1 Plaques			
Individuals with solely	27 (14%)	12 (20%)	0.22
calcified plaques			
Individuals with a	15 (8%)	7 (12%)	0.31
combination of calcified			
and non-calcified plaques			
Total number of plaques			
Calcific	61(80%)	24 (63%)	0.08
Mixed morphology	15 (18%)	14 (37%)	0.03
Non calcific only	1 (0.5%)	0	n/a
Left main plaque	4 (2%)	1 (2%)	0.86
Left anterior descending	36 (16%)	9 (15%)	0.58
Circumflex coronary artery	6 (1%)	3 (5.1%)	0.46
Right coronary artery	11 (5.1%)	4 (6.8%)	0.74
Number of vessels			
1-vessel disease	32 (16%)	13 (22%)	
2-vessel disease	7 (4%)	2 (3.4%)	0.20
3-vessel disease	3 (1.5%)	4 (6.8%)	
Stenosis >50%	0 (0%)	0 (0%)	
	1		1

It is made available under a	CC-BY	Y 4.0 International license .	

Stenosis 25-49%	6 (3%)	4 (7%)	0.22
Stenosis <25%	36 (18%)	15 (25%)	

545

- 546 AU= Agatston Units; CACS= Coronary Artery Calcium Score; CAC = Coronary artery
- 547 calcium; CAD = Coronary artery disease, FAI-RCA = Fat Attenuation Index in the Right
- 548 Coronary Artery; LMCA = Left main coronary artery. Values are presented as n
- 549 (percentage) or medians (Interquartile range 25%, 75%).
- 550

- 552 **Table 3**. Comparison of plaque volume, burden and composition in master athletes
- and controls. Values are presented as median and 75%-25% interquartile range (IQR)
- 554 if not otherwise indicated.

	Athletes	Controls	p value				
	N=35	N=10					
Volume, mm ³ (IQR)							
Vessel	163 (93-283)	270 (110-379)	0.11				
Total Plaque	16 (3-56)	49 (5-142)	0.08				
Calcific plaque	3.6 (1.3-14)	4.63 (2-21.6)	0.53				
NC plaque	0 (0-32)	16.99 (0-132)	0.29				
LD NC plaque	0 (0-2.1)	0.67 (0-13.5)	0.34				
Necrotic Core	0 (0-2.2)	0.65 (0-13.5)	0.34				
Fibrous Fatty	0 (0-14.6)	2.7 (0-41.6)	0.4				
Fibrous	0 (0-9)	10.9 (0-36)	0.21				
Dense Calcium	3.6 (1.3-18)	5.8 (2.8-28.6)	0.36				
Contrast Density	15.2 (7.3-32)	20.8 (12-34)	0.56				
Drop							
Burden, % (IQR)							
Total Plaque	10.8 (2.8-21)	15.4 (4.6-28)	0.46				
Calcific Plaque	1.8 (1.1-6.9)	4.1 (0.6-6.1)	0.027				
NC Plaque	0 (0-19)	4.5 (0-24)	0.39				
LD-NCP Plaque	0 (0-1.5)	0.2 (0-2.3)	0.51				
Composition, % (IQ	R)						
Calcific Plaque	100 (8.2-100)	70.1 (4.3-100)	0.65				
NC Plaque	0 (0-91.4)	29.8 (0-93.5)	0.51				
LD NCP Plaque	0 (0-10.1)	1.2 (0-15.3)	0.51				
Coronary							
Inflammation	N=151	N=36					
FAI_RCA	-64 ± 7.9	-69 ± 8.4	0.002				

555 CP= calcific plaque, NC= non-calcific, LD= low density

557	Table 4.	Determinants	of	coronary	atherosclerosis	in	female	master	athletes.
558	Univariate	e and multivaria	ite	analysis.					

	CACS=0	CACS>0	Univari	Multi-
	N=155	N=41	ate	variate
				R ² =0.21
Age	53 ± 0.6	59.7 ± 1.5	<0.001	<0.001
Menopausal	107 (69%)	32 (78%)	0.29	
BMI (kg/m ²)	21.3 (20-22.6)	21.6 (20-23.4)	0.62	
Years of Exercise	31 ± 11	35 ± 12	0.047	
Hours per Week	8 (7-10)	8 (7-11)	0.93	
Days per Week	6 (5-6)	5.3 (4-6)	0.24	
Total Competitions	76 (30-185)	100 (50-145	0.66	
Total METS min/w	7239 (4784-	6835 (4743-	0.59	
	10932)	9498)		
Vigorous METS min/w	2880 (2880-	2880 (2160-	0.92	
	4800)	4800)		
PTH levels (pmol/L)	7.3 (6-9.4)	7.7 (5.9-9.8)	0.66	
Total cholesterol	5.1 (4.7 – 6)	5.4 (4.7 – 5.9)	0.50	
HDL-C (mmol/L)	2.5 ± 0.8	2.1 ± 0.7	0.007	0.011
Peak VO2 (ml/min/kg)	41.6 ±6.18	38.8 ±8.35	0.020	
Peak VO2 predicted (%)	163 ± 23.4	165.5 ± 28.4	0.90	
FAI _{RCA} (HU)	-63.6 ± 7.3	-66.7 ± 8.8	0.024	
Resting SBP (mmHg)	113 ± 14	122 ± 16	<0.001	0.012
SBP>190 mmHg [#]	36 (23%)	13 (32%)	0.28	

559

560 FAI_{RCA} = Fat Attenuation Index in the Right Coronary Artery; HDL-C= High Density

Lipoprotein Cholesterol; HU = Hounsfield Units; METS = Metabolic Equivalents; PTH = 561

Parathyroid Hormone; VO2 = Oxygen Consumption, SBP: Systolic blood pressure. 562

indicates SBP values at peak exercise. Values are presented as n (percentage), 563

medians (Interquartile range 25%, 75%) or mean ± standard deviation. 564

565

Figure 1. Coronary artery calcium (CAC) score characteristics in female master athletes and controls. The prevalence of CAC score categories did not differ between athletes versus controls (panel A), whereas athletes had a significantly lower prevalence of a CAC score exceeding the 50th and 75th Multi-Ethnic Study of Atherosclerosis (MESA) percentile (panel B).



575 Figure 2. A. Presence of coronary atherosclerotic plaque and degree of stenosis in

576 female master athletes and controls. **B.** Plaque morphology in female athletes (76

577 coronary plaques) and relatively sedentary males (38 coronary plaques).



583 Figure 3. Quantitative characteristics of coronary atherosclerotic plaque in female master athletes and controls. Total plaque volume (A), calcified plaque volume (B), 584 non-calcified plaque volume (C) and low-density calcified plaque volume (D) did not 585 differ between athletes versus controls. 586





590

Figure 4. Fat attenuation index (FAI) measured in female master athletes and controls. Female athletes showed a significantly higher degree of coronary inflammation than controls (panel A). Athletes with a zero coronary artery calcium score (CACS) showed a higher FAI than athletes with CACS>0 (Panel B).



595

596

597

598

599

600

601

Figure 5. Coronary atherosclerosis in relation to age in female master athletes per

604 different age groups. The presence of coronary artery calcium score (CACS) >100 AU

and >400 AU was almost confined to female master athletes > 65 years old.

